Lurasidone 20 mg daily + Lurasidone + Placebo

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Autism

Conditions

Autism

Trial Timeline

Aug 1, 2013 → Nov 1, 2014

NCT ID

NCT01911442

About Lurasidone 20 mg daily + Lurasidone + Placebo

Lurasidone 20 mg daily + Lurasidone + Placebo is a phase 3 stage product being developed by Sumitomo Pharma for Autism. The current trial status is completed. This product is registered under clinical trial identifier NCT01911442. Target conditions include Autism.

What happened to similar drugs?

0 of 9 similar drugs in Autism were approved

Approved (0) Terminated (2) Active (7)

🔄Cariprazine + PlaceboAbbViePhase 3

❌Balovaptan + PlaceboRochePhase 3

🔄KarXT + KarX-EC + KarXT + KarX-EC Matching PlaceboBristol Myers SquibbPhase 3

🔄Brexpiprazole + PlaceboLundbeckPhase 3

🔄BrexpiprazoleLundbeckPhase 3

❌RG1068 (Synthetic Human Secretin)RepligenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01911442	Phase 3	Completed	Aug 1, 2013	Nov 1, 2014	Autism

Competing Products

20 competing products in Autism

See all competitors

Product	Company	Stage	Hype Score
Ketamine + Placebo	Roivant Sciences	Phase 1	26
Cord Tissue Mesenchymal Stromal Cells	Cryo-Cell	Phase 2	25
Suramin Sodium	PaxMedica	Phase 2	25
NORSPAN Buprenorphine Transdermal Patchs for Very-low dose group + NORSPAN Buprenorphine Transdermal Patchs for Lower dose group + NORSPAN Buprenorphine Transdermal Patchs for higher dose group	Shionogi	Pre-clinical	33
Cariprazine + Placebo	AbbVie	Phase 3	40
Cariprazine	AbbVie	Phase 1	29
Omalizumab Injection [Xolair]	Novartis	Phase 1	21
RO7017773	Roche	Phase 1	29
Placebo + RO7017773	Roche	Phase 2	35
Balovaptan	Roche	Phase 1	21
Balovaptan	Roche	Phase 1	21
Balovaptan + Esomeprazole	Roche	Phase 1	29
Placebo + RG7314	Roche	Phase 2	35
Placebo + RO5285119	Roche	Phase 2	27
Balovaptan + Placebo	Roche	Phase 3	32
KarXT + KarX-EC + KarXT + KarX-EC Matching Placebo	Bristol Myers Squibb	Phase 3	47
Aripiprazole	Bristol Myers Squibb	Phase 2	35
KarXT + KarX-EC + KarXT + KarX-EC Matching Placebo	Bristol Myers Squibb	Phase 3	47
Brexpiprazole + Placebo	Lundbeck	Phase 3	37
Brexpiprazole	Lundbeck	Phase 3	37